Evidence map›Paper›PMID 25400441›Full record

ReviewWorld journal of gastroenterology2014

Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.

Xiao-Yi Wang, Feng Yang, Chen Jin, De-Liang Fu

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Molecular Imaging: Unveiling Metabolic Abnormalities in Pancreatic Cancer.International journal of molecular sciences · 2025
    Review
  6. Review
  7. ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study.European journal of nuclear medicine and molecular imaging · 2025
    Article
  8. Case Report:Frontiers in medicine · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.European journal of nuclear medicine and molecular imaging · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Comparison of the diagnostic efficacy ofEuropean journal of nuclear medicine and molecular imaging · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xiao-Yi WangXiao-Yi Wang, Feng Yang, Chen Jin, De-Liang Fu, Pancreatic Disease Institute, Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Feng YangXiao-Yi Wang, Feng Yang, Chen Jin, De-Liang Fu, Pancreatic Disease Institute, Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Chen JinXiao-Yi Wang, Feng Yang, Chen Jin, De-Liang Fu, Pancreatic Disease Institute, Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
De-Liang FuXiao-Yi Wang, Feng Yang, Chen Jin, De-Liang Fu, Pancreatic Disease Institute, Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Huashan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is one of the most common gastrointestinal tumors, with its incidence staying at a high level in both the United States and China. However, the overall 5-year survival rate of pancreatic cancer is still extremely low. Surgery remains the only potential chance for long-term survival. Early diagnosis and precise staging are crucial to make proper clinical decision for surgery candidates. Despite advances in diagnostic technology such as computed tomography (CT) and endoscopic ultrasound, diagnosis, staging and monitoring of the metabolic response remain a challenge for this devastating disease. Positron emission tomography/CT (PET/CT), a relatively novel modality, combines metabolic detection with anatomic information. It has been widely used in oncology and achieves good results in breast cancer, lung cancer and lymphoma. Its utilization in pancreatic cancer has also been widely accepted. However, the value of PET/CT in pancreatic disease is still controversial. Will PET/CT change the treatment strategy for potential surgery candidates? What kind of patients benefits most from this exam? In this review, we focus on the utility of PET/CT in diagnosis, staging, and assessment of resectability of pancreatic cancer. In addition, its ability to monitor metabolic response and recurrence after treatment will be emphasis of discussion. We hope to provide answers to the questions above, which clinicians care most about.

Indexed as

Positron-Emission TomographyTomography, X-Ray ComputedHumansMultimodal ImagingNeoplasm Recurrence, LocalNeoplasm StagingPancreatic NeoplasmsPatient SelectionPredictive Value of TestsTreatment OutcomeDiagnosisMetabolic responsePancreatic cancerPosition emission tomography/computed tomographyStaging

Identifiers

PMID25400441
PMCPMC4229522
OpenAlexW2071748391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.